Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers | terminated | Phase 1 | 27 | Guido A. Davidzon, MD, SMOTHER | 1 | Aug 12, 2024 |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 184 | CelgeneINDUSTRY | 7 | Jul 26, 2024 | clinicaltrials |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM | terminated | Phase 1 / Phase 2 | 8 | SonALAsense, Inc.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 | 20 | CelgeneINDUSTRY | 2 | Jul 5, 2024 | clinicaltrials |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 26 | Basilea PharmaceuticaINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT03451825 | Phase I/II Study of Avelumab in Pediatric Cancer Participants | terminated | Phase 1 | 21 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Jun 24, 2024 | clinicaltrials |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | terminated | Phase 1 | 14 | Nicholas ButowskiOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | terminated | Phase 1 / Phase 2 | 5 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM | terminated | Phase 1 / Phase 2 | 8 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | terminated | Phase 1 | 3 | Monteris MedicalINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | terminated | Phase 1 | 7 | Providence Health & ServicesOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT00089245 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | terminated | Phase 1 | 177 | Y-mAbs TherapeuticsINDUSTRY | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05394558 | AsiDNA Children, Adolescents and Young Adults(AsiDNA) | terminated | Phase 1 / Phase 2 | 8 | Institut CurieOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04096716 | Mapping Draining Lymph Nodes in CNS Malignancies | terminated | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | terminated | Phase 1 | 4 | University of NebraskaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02833701 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | terminated | Phase 1 | 9 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02659800 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | terminated | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | terminated | Phase 1 | 2 | AeRang KimOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | terminated | Phase 1 | 7 | OncoSynergy, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03267836 | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | terminated | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | terminated | Phase 1 | 12 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 6 | Jun 13, 2023 | clinicaltrials |
| NCT03332355 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | terminated | Phase 1 | 18 | Vanquish Oncology, Inc.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | terminated | Phase 1 / Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | terminated | Phase 1 | 16 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma(FOLAGLI) | terminated | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | terminated | Phase 1 | 3 | Daniel LandiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | terminated | Phase 1 / Phase 2 | 12 | Brown UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | terminated | Phase 1 | 2 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2024source: clinicaltrials